📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
0 analysed today
FollowTelegram
0
Today
152,139
All-time analysed
43,645
Positive
6,747
Negative
92,898
Neutral
8,781
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
226 announcements match the current filters (relevance ≥ 5).
APL Apollo Q4FY26 PAT Rises 21% to ₹3.5Bn; FY26 Net Profit Surges 59% YoY
APL Apollo Tubes reported a robust performance for Q4FY26, with net profit increasing 21% YoY to ₹3.5 billion and revenue growing 14% to ₹62.7 billion. For the full year FY26, the company achieved a massive 59% growth in PAT to ₹12.0 billion, supported by an 11% volume growth and a 36% jump in EBITDA per ton to ₹5,161. The company maintains a strong balance sheet with a net cash position of ₹15.3 billion and zero net working capital days. Management has outlined a clear growth path to reach 8 million tons of capacity by FY28, up from the current 5 million tons.
Key Highlights
Q4FY26 EBITDA grew 24% YoY to ₹5.1 billion with EBITDA per ton rising 14% to ₹5,525.
Full-year FY26 Net Profit reached ₹12.0 billion, a 59% increase over FY25.
Return on Capital Employed (ROCE) improved significantly to 37.3% in FY26 from 24.5% in FY25.
Net cash position strengthened to ₹15.3 billion compared to ₹3.1 billion in the previous year.
Capacity expansion plan targeting 8 million tons by FY28 through greenfield and brownfield projects.
👀 What to Watch
Investors should take note of the company's superior capital efficiency and debt-free status, which provides a strong cushion for its aggressive expansion plans. The stock remains a key play on India's infrastructure and structural steel demand, particularly with the upcoming 3 million ton capacity addition.
APL Apollo Recommends ₹8.50 Dividend and Plans Non-Core Asset Divestment
APL Apollo Tubes has recommended a final dividend of ₹8.50 per share (425%) for FY26 following its board meeting. The company is streamlining its corporate structure by initiating the voluntary liquidation of APL Apollo Mart Limited, which contributed a negligible 0.04% to consolidated revenue. Furthermore, the board granted in-principle approval to divest its real estate subsidiary, Blue Ocean Projects, to redeploy capital into its core manufacturing operations. Four independent directors have also been re-appointed for second five-year terms, ensuring leadership continuity.
Key Highlights
Recommended a final dividend of ₹8.50 per equity share (425% of face value) for FY26.
Initiated voluntary liquidation of APL Apollo Mart Limited, which held a net worth of ₹111.72 crore.
Approved divestment of real estate subsidiary Blue Ocean Projects to unlock capital for core business.
Re-appointed four Independent Directors for second 5-year terms starting in 2026 and 2027.
Reported audited financial results for FY26 with an unmodified auditor's opinion.
👀 What to Watch
Investors should view the dividend and the strategic exit from non-core real estate assets as positive steps toward capital efficiency and core business focus. Monitor the detailed FY26 earnings report for growth trends in the manufacturing segment.
APL Apollo Recommends ₹8.50 Final Dividend and Announces Corporate Restructuring
APL Apollo Tubes has recommended a final dividend of ₹8.50 per equity share (425% of face value) for FY26. The company is also streamlining its operations by initiating the voluntary liquidation of its non-operational subsidiary, APL Apollo Mart Limited, and divesting its real estate holding subsidiary, Blue Ocean Projects. These moves are part of a capital allocation strategy to unlock funds and redeploy them into the core manufacturing business. Additionally, the board has re-appointed four independent directors for second five-year terms, ensuring management continuity.
Key Highlights
Recommended a final dividend of ₹8.50 per equity share of ₹2 face value for the financial year ended March 31, 2026.
Initiated voluntary liquidation of APL Apollo Mart Limited, which contributed only 0.04% to consolidated revenue.
Approved divestment of Blue Ocean Projects Private Limited to unlock capital from real estate assets for core business use.
Re-appointed four Independent Directors, including former IAS and IRS officers, for second 5-year terms.
Statutory Auditors provided an unmodified opinion on the audited standalone and consolidated financial results for FY26.
👀 What to Watch
Investors should benefit from the healthy dividend payout and the company's strategic focus on core manufacturing by exiting non-core assets. Maintain a positive outlook as the restructuring aims to improve capital efficiency and simplify the group structure.
APL Apollo Recommends ₹8.50 Dividend and Approves Strategic Restructuring
APL Apollo Tubes has recommended a final dividend of ₹8.50 per share (425% of face value) for FY26 following its board meeting. The company is initiating a strategic restructuring by liquidating its non-operational subsidiary, APL Apollo Mart Limited, which contributed only 0.04% to consolidated revenue. Furthermore, the board granted in-principle approval to divest its real estate holding subsidiary, Blue Ocean Projects Private Limited, to unlock capital for its core manufacturing business. The company also ensured leadership continuity by re-appointing four independent directors for second five-year terms.
Key Highlights
Recommended a final dividend of ₹8.50 per equity share of ₹2 face value (425% payout).
Initiated voluntary liquidation of APL Apollo Mart Limited, a subsidiary with minimal revenue of ₹9.02 crore (0.04% of total).
Approved divestment of real estate subsidiary Blue Ocean Projects Private Limited to redeploy capital into core operations.
Re-appointed four Independent Directors, including former IAS and IRS officers, for second 5-year terms.
Statutory auditors provided an unmodified opinion on the consolidated financial results for the year ended March 31, 2026.
👀 What to Watch
Investors should find the healthy dividend payout and the management's focus on core manufacturing via subsidiary rationalization encouraging. The divestment of non-core real estate assets is a positive step toward better capital allocation.
Apollo Hospitals Receives NCLT Order for Keimed-Healthco Merger; Meetings Set for May 27, 2026
Apollo Hospitals has received the NCLT order regarding its composite scheme of arrangement involving Apollo Healthco, Keimed Private Limited, and Apollo Healthtech. The tribunal has scheduled meetings for equity shareholders and unsecured creditors of the company on May 27, 2026, to vote on the restructuring proposal. This scheme aims to integrate the pharmacy distribution business of Keimed with Apollo's digital health and pharmacy platform. A high consent level of 90.96% from certain secured creditors has already been noted by the tribunal.
Key Highlights
NCLT Chennai Bench issued the order on April 15, 2026, for the composite scheme of arrangement.
Equity shareholders' meeting for Apollo Hospitals is scheduled for May 27, 2026, at 2:30 PM.
Unsecured creditors' meeting for the company is set for May 27, 2026, at 11:00 AM.
Secured creditors' meeting for Applicant Company 1 is scheduled for May 27, 2026, at 10:00 AM.
Consent of 90.96% from secured creditors led to the dispensation of meetings for certain applicant entities.
👀 What to Watch
Investors should monitor the outcome of the shareholder and creditor meetings on May 27, 2026, as this restructuring is a key driver for value unlocking in Apollo's pharmacy and digital health ecosystem.
Apollo Hospitals Receives NCLT Order to Convene Meetings for Composite Scheme on May 27, 2026
Apollo Hospitals Enterprise Limited (AHEL) has received an order from the NCLT Chennai regarding its composite scheme of arrangement involving Apollo Healthco, Keimed, and Apollo Healthtech. The tribunal has scheduled the meeting for equity shareholders and unsecured creditors of AHEL for May 27, 2026. Although the company sought to dispense with the secured creditors' meeting citing 90.96% consent, the NCLT has directed that the meeting must proceed on May 27, 2026. This procedural step is crucial for the proposed restructuring of the group's pharmacy and digital health businesses.
Key Highlights
NCLT has fixed May 27, 2026, at 2:30 PM for the meeting of Apollo Hospitals' equity shareholders.
The meeting for unsecured creditors of Apollo Hospitals is scheduled for May 27, 2026, at 11:00 AM.
Tribunal rejected the request to dispense with the secured creditors' meeting despite 90.96% consent already obtained.
Meetings for other involved entities (Transferor Companies) are scheduled for May 26, 2026.
The scheme remains subject to final approvals from shareholders, creditors, and regulatory authorities.
👀 What to Watch
Investors should track the outcome of the shareholder meeting on May 27, 2026, as this restructuring is a key milestone for the company's long-term strategy. No immediate portfolio action is required until the voting results and subsequent regulatory clearances are finalized.
Apollo Micro Systems Receives Lifetime License for Arms & Munitions Manufacture
Apollo Micro Systems (AMS) has been granted a lifetime license by the Government of India (DPIIT) to manufacture high-value strategic weapon systems, including missiles, torpedoes, and loitering munitions. This license authorizes an annual production capacity of 1,000 units per category across two AMS-owned facilities in Hyderabad. The company is strategically transitioning from a provider of embedded subsystems to an end-to-end platform manufacturer of complete weapon systems. This move is supported by its subsidiary, IDL Explosives Limited, which provides critical capabilities in propellants and warhead energetics.
Key Highlights
Granted lifetime license by DPIIT for manufacturing missiles, ATGMs, torpedoes, and loitering munitions
Authorized annual production capacity of 1,000 units per category across two Hyderabad facilities
License covers high-caliber arms (above 12.7mm) including Category I and Category II systems
Strategic shift from subsystem supplier to a full-spectrum weapon system platform manufacturer
Integration with subsidiary IDL Explosives for solid propellants and warhead design
👀 What to Watch
Investors should recognize this as a transformative milestone that significantly expands the company's addressable market and revenue architecture. Monitor the company's progress in securing defense orders for these newly licensed weapon categories.
Apollo Pipes Commences Commercial Production at New Mirzapur Plant
Apollo Pipes Limited has officially commenced commercial production at its new manufacturing facility in Mirzapur, Uttar Pradesh, as of April 14, 2026. This strategic expansion, located near Varanasi, follows a series of planned developments first disclosed in May 2024. The plant is expected to significantly enhance the company's production capacity and market penetration in Northern India. This milestone marks the completion of a multi-year investment cycle aimed at scaling the company's piping and plumbing business.
Key Highlights
Commencement of commercial operations at the Mirzapur plant effective April 14, 2026.
Project execution follows a timeline of regulatory disclosures dating back to May 20, 2024.
Strategic location near Varanasi to optimize distribution and logistics in the Uttar Pradesh region.
The expansion is intended to cater to rising demand in the building materials and infrastructure sectors.
👀 What to Watch
Investors should monitor the plant's capacity utilization rates and its impact on volume growth in the upcoming quarterly financial results. The expansion strengthens the company's competitive position in the regional market.
Apollo Hospitals Acquires Remaining Stake in AHLL for Rs 18.69 Cr; Becomes 100% Subsidiary
Apollo Hospitals Enterprise Limited has completed the acquisition of the remaining stake in its subsidiary, Apollo Health and Lifestyle Limited (AHLL). The company purchased 775,744 equity shares from individual shareholders at a price of Rs 241 per share, amounting to a total consideration of Rs 18.69 crores. This transaction follows previous acquisitions from IFC and IFC EAF, which had already increased the stake to 99.42%. With this final purchase, AHLL has now become a 100% wholly-owned subsidiary of Apollo Hospitals.
Key Highlights
Acquired 775,744 equity shares of Apollo Health and Lifestyle Limited (AHLL) from individual shareholders.
The acquisition was executed at a price of Rs 241 per share, totaling Rs 18.69 crores.
Company's shareholding in AHLL increased from 99.42% to 100% following this transaction.
AHLL is now a wholly-owned subsidiary, simplifying the corporate structure for the retail healthcare business.
👀 What to Watch
Investors should view this as a positive consolidation move that gives Apollo Hospitals full control over its primary care and diagnostic business. No immediate action is required, but it reinforces the company's focus on its retail health growth engine.
Apollo Hospitals Receives NCLT Order for Composite Scheme of Arrangement
Apollo Hospitals Enterprise Limited (AHEL) has received a certified order from the NCLT Chennai Bench regarding its composite scheme of arrangement. The scheme involves the restructuring of Apollo Healthco, Keimed Private Limited, and Apollo Healthtech to streamline the pharmacy distribution and digital health business. The Tribunal has directed AHEL to convene meetings of its equity shareholders and creditors to seek approval for the proposed arrangement. This is a critical step in the company's long-term strategy to consolidate its pharmacy supply chain and digital platform.
Key Highlights
NCLT order dated March 26, 2026, received by the company on April 9, 2026, regarding the composite scheme.
The arrangement involves Apollo Hospitals (Demerged Co), Apollo Healthco (Transferor 1), Keimed (Transferor 2), and Apollo Healthtech (Resultant Co).
Tribunal directed the convening of a meeting for AHEL equity shareholders via VC/OAVM to vote on the scheme.
Meetings for equity shareholders of Keimed Private Limited and Apollo Healthtech Limited have been dispensed with by the Tribunal.
The restructuring aims to integrate the wholesale distribution business of Keimed with the pharmacy platform of Apollo Healthco.
👀 What to Watch
Investors should vote in favor of the scheme as it is expected to simplify the corporate structure and unlock value in the pharmacy and digital health segments. Monitor the upcoming shareholder meeting date and subsequent voting results for further clarity on the execution timeline.
Apollo Micro Systems Completes Blast Trials for Limpet Mines; Sole Indian Developer for Navy
Apollo Micro Systems has successfully completed blast trials for Limpet Mines, which are specialized diver-carried mines used in naval defense. The company is currently the only Indian firm to have successfully developed this product for the Indian Navy, creating a significant competitive moat. This milestone allows the company to offer a complete spectrum of underwater mines, ranging from shallow to deep-water categories. This development significantly strengthens the company's portfolio in the niche underwater Electronic Warfare systems segment.
Key Highlights
Successfully completed blast trials for Limpet Mines used in Naval Defence.
Recognized as the only Indian company to develop this specific product for the Indian Navy.
Expands product range to cover the complete spectrum of underwater mines (Shallow, Deep, and Limpet).
Strengthens the company's technological positioning in underwater Electronic Warfare systems.
👀 What to Watch
Investors should view this as a major R&D milestone that positions the company for exclusive defense contracts. Monitor for upcoming order book additions specifically related to naval underwater systems.
Apollo Hospitals Gets NCLT Approval to Convene Meetings for Composite Scheme of Arrangement
Apollo Hospitals Enterprise Limited (APOLLOHOSP) has received an order from the NCLT Chennai Bench regarding its composite scheme of arrangement involving Apollo Healthco, Keimed, and Apollo Healthtech. The Tribunal has directed the company to convene meetings for its equity shareholders, secured creditors, and unsecured creditors to seek approval for the restructuring. As of June 2025, the company reported a paid-up share capital of ₹71.89 crore consisting of 14.37 crore equity shares. This regulatory milestone is a key step in the company's plan to consolidate its pharmacy distribution and digital health platforms.
Key Highlights
NCLT Chennai Bench allowed the application for the composite scheme of arrangement in an order dated March 26, 2026.
The Tribunal directed the convening of meetings for equity shareholders and creditors of Apollo Hospitals to vote on the scheme.
Meetings for shareholders of Apollo Healthco, Keimed, and Apollo Healthtech have been dispensed with by the Tribunal.
The scheme involves the demerger and consolidation of health-tech and pharmacy distribution assets into a resultant company.
Final implementation is subject to the approval of shareholders, creditors, and a final sanction order from the NCLT.
👀 What to Watch
Investors should monitor the outcomes of the upcoming shareholder and creditor meetings as this restructuring is intended to unlock value in the digital health segment. No immediate action is required, but the progress indicates the consolidation plan is on track.
Apollo Hospitals to Set Up Multi-Speciality Hospital in Dwarka, Delhi on 9.33-Acre Land
Apollo Hospitals has approved the establishment of a new super-speciality hospital in Dwarka, New Delhi, on a 9.33-acre land parcel leased from the Delhi Development Authority. The project will be executed through a Special Purpose Vehicle (SPV) under a 55-year license agreement. An annual license fee of Rs. 33.3 crores will be payable starting from the fifth year, following a moratorium period, with annual escalations thereafter. This strategic move significantly expands Apollo's footprint in the high-demand National Capital Region.
Key Highlights
Secured 9.33 acres of land in Dwarka, New Delhi, from DDA on a 55-year license basis.
Annual license fee of Rs. 33.3 crores starting from the 5th year with annual escalations.
Project to be implemented in a phased manner via a dedicated Special Purpose Vehicle (SPV).
Formal license agreement to be executed within one year from the board approval.
👀 What to Watch
This expansion is a positive long-term growth catalyst for Apollo's presence in North India. Investors should track updates on project CAPEX and the expected timeline for the first phase of operations.
APL Apollo Reports All-time High Q4FY26 Sales Volume of 9.25 Lakh Tons, Up 9% YoY
APL Apollo Tubes achieved its highest-ever quarterly sales volume of 924,881 tons in Q4FY26, marking a 9% growth compared to the previous year. For the full fiscal year FY26, the company reported a total sales volume of 3,491,243 tons, representing an 11% year-on-year increase. Growth was robust across key segments, particularly in the General structural and Rust-proof categories. These record volumes indicate strong demand in the building materials sector and effective utilization of the company's 4.5 million ton capacity.
Key Highlights
Q4FY26 sales volume reached an all-time high of 924,881 tons, a 9% increase over Q4FY25.
Full-year FY26 sales volume grew 11% YoY to 3,491,243 tons from 3,157,978 tons in FY25.
The 'General' structural segment grew 17% YoY in Q4FY26, reaching 413,574 tons.
Apollo Z Rust-proof segment contributed 777,705 tons for the full year FY26.
The company operates 11 manufacturing facilities with a total capacity of 4.5 million tons.
👀 What to Watch
Investors should take this as a positive signal of market leadership and demand resilience; however, wait for the full financial results to assess if volume growth translated into margin expansion. The stock remains a strong proxy for India's infrastructure and construction growth.
Apollo Pipes Postpones Mirzapur Plant Commercial Production to Late April 2026
Apollo Pipes Limited has announced a further delay in the commencement of commercial operations at its new manufacturing facility in Mirzapur, Uttar Pradesh. The company now targets the end of April 2026 for production to begin, contingent upon achieving operational readiness. This announcement follows a series of previous timeline updates dating back to May 2024 and May 2025. Repeated delays in capacity expansion typically defer projected revenue growth and may impact the company's ability to capture market share in the North Indian region as originally planned.
Key Highlights
Commercial production at the Mirzapur (Varanasi) plant is now expected by the end of April 2026.
The project has undergone multiple timeline revisions with previous disclosures in May 2024, May 2025, and January 2026.
Commencement remains subject to final operational readiness at the Uttar Pradesh facility.
The delay impacts the company's strategic expansion plans for the high-demand North Indian market.
👀 What to Watch
Investors should monitor management's commentary in the upcoming quarterly earnings call to understand the specific bottlenecks causing recurring delays. The stock may face short-term pressure as growth triggers from the new capacity are pushed further into the future.
Apollo Hospitals Completes 30.58% Stake Buy in AHLL for Rs 12,540.68 Million
Apollo Hospitals Enterprise Limited has successfully completed the acquisition of a 30.58% equity stake in its subsidiary, Apollo Health and Lifestyle Limited (AHLL). The stake was acquired from International Finance Corporation (IFC) and IFC EAF for a total consideration of Rs 12,540.68 million. Following this transaction, Apollo Hospitals' effective shareholding in AHLL has increased significantly to 99.42%. This move consolidates the company's control over its retail healthcare and primary care business segments.
Key Highlights
Acquisition of 41,650,638 equity shares representing a 30.58% stake in AHLL.
Total purchase consideration of Rs 12,540.68 million paid to IFC and IFC EAF.
Effective shareholding in the subsidiary AHLL increased to 99.42%.
Transaction completed following necessary approval from the Competition Commission of India (CCI).
Consolidates ownership in the retail healthcare vertical including clinics and diagnostics.
👀 What to Watch
This consolidation of ownership in a key growth subsidiary is a positive long-term move; investors should monitor AHLL's contribution to the consolidated bottom line. The stock may see positive sentiment as the company simplifies its corporate structure and gains full control over AHLL's cash flows.
Apollo Micro Systems to List 28.89 Lakh Equity Shares from March 19
Apollo Micro Systems has received trading approval for 28,89,044 equity shares issued on a preferential basis to non-promoters. These shares were issued at a price of Rs. 114 per share, including a premium of Rs. 113, following the conversion of warrants. The shares will be admitted for trading on both NSE and BSE starting March 19, 2026. These new shares are subject to a mandatory lock-in period until September 19, 2026.
Key Highlights
Listing of 28,89,044 equity shares with a face value of Re. 1 each
Shares issued at a total price of Rs. 114 per share (Rs. 113 premium)
Allotment resulted from the conversion of warrants previously issued to non-promoters
Trading commences on NSE and BSE effective from March 19, 2026
Specific lock-in period for these shares is valid until September 19, 2026
👀 What to Watch
Investors should monitor the slight equity dilution resulting from this conversion. No immediate action is required as this is a procedural listing of previously announced preferential allotments.
Apollo Micro Systems Receives Trading Approval for 28.89 Lakh Equity Shares
Apollo Micro Systems has received trading approval from NSE and BSE for 28,89,044 equity shares of Re. 1/- each. These shares were issued to non-promoters on a preferential basis following the conversion of warrants. The shares were issued at a price of Rs. 114 per share, including a premium of Rs. 113. Trading for these new securities is scheduled to commence on March 19, 2026, with a lock-in period ending on September 19, 2026.
Key Highlights
Approval for listing and trading of 28,89,044 equity shares on NSE and BSE.
Shares issued at Rs. 114 per share (Face Value Re. 1 + Premium Rs. 113).
Issued to non-promoters pursuant to the conversion of warrants.
Trading effective from March 19, 2026, with a lock-in period until September 19, 2026.
Total distinctive numbers for the new shares range from 354391701 to 357280744.
👀 What to Watch
Investors should monitor the slight equity dilution following this warrant conversion. The conversion at Rs. 114 per share reflects institutional or high-net-worth individual interest at that valuation level.
Gujarat Apollo Targets ₹300 Cr Revenue in 3 Years via Dual-Engine Growth Strategy
Gujarat Apollo Industries has unveiled a strategic roadmap to achieve over ₹300 crore in combined revenue within the next three fiscal cycles. The company is leveraging its legacy in road-construction and mining equipment (target ₹210 Cr) while diversifying into the high-demand agriculture sector (target ₹90 Cr). A committed capex of ₹26 crore, funded through equity warrant conversion, will be used for facility modernization and capacity expansion by June 2026. This strategy marks the company's return to the road-construction segment following the end of a non-compete agreement.
Key Highlights
Targeting ₹300 Cr+ combined revenue in 3 years and ₹500 Cr+ by 2031
Allocating ₹26 Cr for modernization and expansion, funded via preferential warrant conversion
Expanding into Agri-equipment with a ₹90 Cr revenue target through subsidiaries like Fieldtrack and Ganesh Agro
Restarting the Road-construction equipment business and developing new Pick & Carry cranes
Acquiring a 50% stake in Ganesh Agro Equipment to bolster the agriculture portfolio
👀 What to Watch
Investors should monitor the execution of the ₹26 crore capex and the successful re-entry into the road-construction market. The diversification into agri-equipment offers a balanced risk profile, making the company a potential turnaround play in the industrial sector.
Apollo Pipes Appoints Parag Dadeech as Chief Operating Officer
Apollo Pipes has appointed Mr. Parag Dadeech as the Chief Operating Officer (COO) effective March 02, 2026. Mr. Dadeech is a seasoned professional with over 28 years of global experience in the manufacturing sector, specializing in operations and supply chain management. His academic credentials include a Master's in Chemical Engineering from the University of Tennessee and a certification from IIM Kolkata. This appointment is expected to strengthen the company's operational efficiency and strategic manufacturing initiatives.
Key Highlights
Appointment of Mr. Parag Dadeech as COO and Senior Management Personnel effective March 02, 2026
Brings over 28 years of global experience in manufacturing, operations, and international business
Holds a Master's degree in Chemical Engineering from the University of Tennessee and is a Lean Six Sigma Master Black Belt
Expertise includes Business Excellence, Global Supply Chain, and Capital Projects management
👀 What to Watch
Investors should view this as a positive step toward professionalizing management and improving operational scale. Monitor future quarterly results for improvements in manufacturing margins and supply chain efficiencies under the new leadership.
